Cyclic Nucleotide Phosphodiesterases, Type 4
"Cyclic Nucleotide Phosphodiesterases, Type 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclic nucleotide phosphodiesterase subfamily that is found predominantly in inflammatory cells and may play a role in the regulation of CELL-MEDIATED IMMUNITY. The enzyme family includes over twenty different variants that occur due to multiple ALTERNATIVE SPLICING of the mRNA of at least four different genes.
| Descriptor ID |
D054703
|
| MeSH Number(s) |
D08.811.277.352.640.150.400 D12.644.360.008.400 D12.776.476.008.400
|
| Concept/Terms |
Cyclic Nucleotide Phosphodiesterases, Type 4- Cyclic Nucleotide Phosphodiesterases, Type 4
- Phosphodiesterase-4
- Phosphodiesterase IV
- PDE4 Phosphodiesterases
- Phosphodiesterases, PDE4
- Cyclic Nucleotide Phosphodiesterase PDE4 Family
- Phosphodiesterase 4
- Type 4 Cyclic Nucleotide Phosphodiesterase
|
Below are MeSH descriptors whose meaning is more general than "Cyclic Nucleotide Phosphodiesterases, Type 4".
Below are MeSH descriptors whose meaning is more specific than "Cyclic Nucleotide Phosphodiesterases, Type 4".
This graph shows the total number of publications written about "Cyclic Nucleotide Phosphodiesterases, Type 4" by people in this website by year, and whether "Cyclic Nucleotide Phosphodiesterases, Type 4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 1 | 2 |
| 2017 | 2 | 3 | 5 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cyclic Nucleotide Phosphodiesterases, Type 4" by people in Profiles.
-
CuCl2-catalyzed inexpensive, faster and ligand/additive free synthesis of isoquinolin-1(2H)-one derivatives via the coupling-cyclization strategy: Evaluation of a new class of compounds as potential PDE4 inhibitors. Bioorg Chem. 2021 10; 115:105265.
-
Gut probiotic Lactobacillus rhamnosus attenuates PDE4B-mediated interleukin-6 induced by SARS-CoV-2 membrane glycoprotein. J Nutr Biochem. 2021 12; 98:108821.
-
PdCl2-catalyzed synthesis of a new class of isocoumarin derivatives containing aminosulfonyl / aminocarboxamide moiety: First identification of a isocoumarin based PDE4 inhibitor. Eur J Med Chem. 2021 Oct 05; 221:113514.
-
SARS-CoV-2 Infection Induces Psoriatic Arthritis Flares and Enthesis Resident Plasmacytoid Dendritic Cell Type-1 Interferon Inhibition by JAK Antagonism Offer Novel Spondyloarthritis Pathogenesis Insights. Front Immunol. 2021; 12:635018.
-
Letter to the editor: Immunomodulation by phosphodiesterase-4 inhibitor in COVID-19 patients. Metabolism. 2020 09; 110:154300.
-
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases. J Med Chem. 2017 12 28; 60(24):10026-10046.
-
Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018 Aug; 29(5):441-449.
-
PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. Int J Mol Sci. 2017 Jun 15; 18(6).
-
2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis. Expert Rev Clin Immunol. 2017 05; 13(5):415-423.
-
Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Ann Rheum Dis. 2017 Jun; 76(6):1133-1141.